Analyst Price Targets — QURE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 9:57 am | — | H.C. Wainwright | $80.00 | $47.51 | TheFly | uniQure price target raised to $80 from $50 at H.C. Wainwright |
| June 25, 2026 10:33 am | Uy Ear | Mizuho Securities | $68.00 | $48.85 | StreetInsider | uniQure BV (QURE) PT Raised to $68 at Mizuho |
| June 18, 2026 11:12 am | — | RBC Capital | $65.00 | $48.16 | TheFly | uniQure price target raised to $65 from $35 at RBC Capital |
| June 18, 2026 11:07 am | — | Barclays | $65.00 | $48.16 | TheFly | uniQure upgraded to Overweight from Equal Weight at Barclays |
| June 18, 2026 10:43 am | Joseph Schwartz | Leerink Partners | $70.00 | $48.16 | StreetInsider | uniQure BV (QURE) PT Raised to $70 at Leerink |
| June 18, 2026 10:20 am | Salveen Richter | Goldman Sachs | $46.00 | $48.16 | TheFly | uniQure price target raised to $46 from $14 at Goldman Sachs |
| June 17, 2026 3:46 pm | — | Cantor Fitzgerald | $61.00 | $47.40 | TheFly | uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news |
| May 6, 2026 2:17 pm | Patrick Trucchio | H.C. Wainwright | $50.00 | $21.64 | TheFly | uniQure price target lowered to $50 from $70 at H.C. Wainwright |
| May 5, 2026 3:37 pm | Paul Matteis | Stifel Nicolaus | $28.00 | $20.78 | TheFly | uniQure price target raised to $28 from $14 at Stifel |
| April 30, 2026 10:12 pm | — | Chardan Capital | $37.00 | $19.95 | TheFly | uniQure price target raised to $37 from $31 at Chardan |
Latest News for QURE
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QURE.
U.S. House Trading
No House trades found for QURE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.